Without the benefit of examination and testing, coloplast is precluded from commenting on the condition of the device or the cause of the occurrence.Should additional facts prompt us to alter or supplement any information of conclusions contained in the original mdr or in any prior supplemental reports, a follow-up report will be submitted.
|
This follow-up mdr is created to document the corrected information in outcomes attributed to adverse events and the additional event, device and patient information received and updated method codes.Without the benefit of analyzing the device, qa cannot confirm any observations and cannot comment on the condition of the prosthesis.If the device becomes available, or additional information is received, qa will re-evaluate this complaint in accordance to procedures.However, because qa's examination may not conclusively confirm or disprove the report of retention, qa accepts the physician's observations of such as the reason for surgical intervention.This complaint was forwarded to the contract manufacturer (cm) for review.The cm reviewed the manufacturing records for this device and confirmed that there were no discrepancies that would have contributed to this complaint and verified that the devices from this lot met all specifications prior to release.Management routinely reviews events such as this and monitors complaint levels.Additionally, events of this type are captured in the product risk documentation.Based on this, and because the device is not available for evaluation, no further corrective action is required at this time.
|
Additional information received indicated post-operative urinary retention, precision on treatment : prolongation of hospitalization (for observation) - medication nitrofurantoin 100 mg (1 tablet 2 times/day during 14 days) - intermittent urinary drainage (once day) - revision of the sling on (b)(6) 2016 - no other treatment, status : resolved on (b)(6) 2017.According to the surgeon this event is related to the procedure.
|